These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

960 related items for PubMed ID: 22670901

  • 1. Delamanid for multidrug-resistant pulmonary tuberculosis.
    Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD.
    N Engl J Med; 2012 Jun 07; 366(23):2151-60. PubMed ID: 22670901
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
    von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R.
    Lancet Respir Med; 2019 Mar 07; 7(3):249-259. PubMed ID: 30630778
    [Abstract] [Full Text] [Related]

  • 3. The diarylquinoline TMC207 for multidrug-resistant tuberculosis.
    Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF.
    N Engl J Med; 2009 Jun 04; 360(23):2397-405. PubMed ID: 19494215
    [Abstract] [Full Text] [Related]

  • 4. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients.
    Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, Geiter LJ, Wells CD, Paccaly AJ, Donald PR.
    Int J Tuberc Lung Dis; 2011 Jul 04; 15(7):949-54. PubMed ID: 21682970
    [Abstract] [Full Text] [Related]

  • 5. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China.
    Zhang Q, Liu Y, Tang S, Sha W, Xiao H.
    Cell Biochem Biophys; 2013 Jul 04; 67(3):957-63. PubMed ID: 23546935
    [Abstract] [Full Text] [Related]

  • 6. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
    Blair HA, Scott LJ.
    Drugs; 2015 Jan 04; 75(1):91-100. PubMed ID: 25404020
    [Abstract] [Full Text] [Related]

  • 7. Profile of delamanid for the treatment of multidrug-resistant tuberculosis.
    Szumowski JD, Lynch JB.
    Drug Des Devel Ther; 2015 Jan 04; 9():677-82. PubMed ID: 25678771
    [Abstract] [Full Text] [Related]

  • 8. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J.
    Tuberculosis (Edinb); 2018 Jul 04; 111():20-30. PubMed ID: 30029909
    [Abstract] [Full Text] [Related]

  • 9. Multidrug-resistant tuberculosis and culture conversion with bedaquiline.
    Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B, TMC207-C208 Study Group.
    N Engl J Med; 2014 Aug 21; 371(8):723-32. PubMed ID: 25140958
    [Abstract] [Full Text] [Related]

  • 10. Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.
    Thakare R, Soni I, Dasgupta A, Chopra S.
    Drugs Today (Barc); 2015 Feb 21; 51(2):117-23. PubMed ID: 25756067
    [Abstract] [Full Text] [Related]

  • 11. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis.
    Sotgiu G, Pontali E, Centis R, D'Ambrosio L, Migliori GB.
    Expert Rev Anti Infect Ther; 2015 Mar 21; 13(3):305-15. PubMed ID: 25645397
    [Abstract] [Full Text] [Related]

  • 12. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M, Mok J, Kim DK, Shim TS, Koh WJ, Jeon D, Lee T, Lee SH, Kim JS, Park JS, Lee JY, Kim SY, Lee JH, Jo KW, Jhun BW, Kang YA, Ahn JH, Kim CK, Shin S, Song T, Shin SJ, Kim YR, Ahn H, Hahn S, Won HJ, Jang JY, Cho SN, Yim JJ.
    Trials; 2019 Jan 16; 20(1):57. PubMed ID: 30651149
    [Abstract] [Full Text] [Related]

  • 13. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS, Jeong BH, Koh WJ.
    Expert Opin Pharmacother; 2015 Feb 16; 16(2):253-61. PubMed ID: 25327169
    [Abstract] [Full Text] [Related]

  • 14. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE, Rosenkranz SL, Conradie F, Moran L, Hafner R, von Groote-Bidlingmaier F, Lama JR, Shenje J, De Los Rios J, Comins K, Morganroth J, Diacon AH, Cramer YS, Donahue K, Maartens G, AIDS Clinical Trials Group (ACTG) A5343 DELIBERATE Study Team.
    Lancet Infect Dis; 2021 Jul 16; 21(7):975-983. PubMed ID: 33587897
    [Abstract] [Full Text] [Related]

  • 15. Effect of Bedaquiline and Delamanid Pharmacokinetics on Sputum Culture Conversion and Adverse Events in Drug-Resistant Tuberculosis.
    Bhatnagar AK, Hemanthkumar AK, Muthu Vijayalakshmi M, Vohra V, Padmapriyadarsini C, Ramesh PM, Taneja G, Chavan VN, Jeyadeepa B, Bhui NK, Solanki R.
    Ther Drug Monit; 2024 Jun 01; 46(3):363-369. PubMed ID: 38161267
    [Abstract] [Full Text] [Related]

  • 16. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
    Mohr E, Ferlazzo G, Hewison C, De Azevedo V, Isaakidis P.
    Lancet Infect Dis; 2019 May 01; 19(5):470. PubMed ID: 31034392
    [No Abstract] [Full Text] [Related]

  • 17. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
    Franke MF, Khan P, Hewison C, Khan U, Huerga H, Seung KJ, Rich ML, Zarli K, Samieva N, Oyewusi L, Nair P, Mudassar M, Melikyan N, Lenggogeni P, Lecca L, Kumsa A, Khan M, Islam S, Hussein K, Docteur W, Chumburidze N, Berikova E, Atshemyan H, Atwood S, Alam M, Ahmed S, Bastard M, Mitnick CD.
    Am J Respir Crit Care Med; 2021 Jan 01; 203(1):111-119. PubMed ID: 32706644
    [Abstract] [Full Text] [Related]

  • 18. Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea.
    Mok J, Kang H, Hwang SH, Park JS, Kang B, Lee T, Koh WJ, Yim JJ, Jeon D.
    J Antimicrob Chemother; 2018 Feb 01; 73(2):503-508. PubMed ID: 29069496
    [Abstract] [Full Text] [Related]

  • 19. Current Status of Delamanid in the Management of MDR Tuberculosis.
    Karekar SR, Marathe PA.
    J Assoc Physicians India; 2018 Jul 01; 66(7):72-75. PubMed ID: 31325268
    [Abstract] [Full Text] [Related]

  • 20. Undergraduate Medical Teaching: Time to integrate?
    Ravikirti, Sharma S.
    J Assoc Physicians India; 2018 Aug 01; 66(8):85-86. PubMed ID: 31324092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.